Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Treatment eligibility determines whether a person with dementia can access a specific medication, therapy, clinical trial, or intervention—and this distinction fundamentally shapes health outcomes. When a patient meets eligibility criteria for a new Alzheimer’s disease medication, for example, they may gain access to a treatment that slows cognitive decline by 35 percent; when they don’t meet criteria, that option becomes unavailable regardless of how much they might benefit. Eligibility requirements exist for scientific, legal, and practical reasons, but they also create real barriers that affect who gets treated and how quickly.
Understanding treatment eligibility matters because it directly impacts decisions about care planning, timing of interventions, and realistic expectations for managing dementia. A person in early cognitive decline might qualify for certain preventive treatments and clinical trials, while someone further along in the disease may only qualify for symptom-management approaches. Family caregivers and patients need to understand these thresholds—not to game the system, but to make informed decisions about seeking diagnosis early, considering experimental options, and planning with healthcare providers about what treatments are actually available to them.
Table of Contents
- How Eligibility Criteria Define Access to Dementia Treatments
- Why Biomarkers Have Become Central to Modern Eligibility
- The Role of Cognitive Testing in Determining Who Qualifies
- Insurance and Coverage Eligibility: A Separate Barrier
- Clinical Trial Eligibility: Opportunity and Exclusion
- Equity, Demographics, and Eligibility Gaps
- The Future of Treatment Eligibility: Toward More Precision and Access
- Conclusion
- Frequently Asked Questions
How Eligibility Criteria Define Access to Dementia Treatments
Eligibility criteria are the clinical, demographic, and practical requirements that determine who can receive a specific treatment. For medications like aducanumab or lecanemab, eligibility hinges on factors including cognitive test scores, amyloid biomarker status (measured through PET scans or cerebrospinal fluid analysis), age, kidney function, and MRI findings. A 72-year-old with documented amyloid pathology on PET and mild cognitive impairment may qualify for lecanemab, while an 85-year-old with the same biomarkers might not, depending on overall health and medication interactions. These eligibility requirements aren’t arbitrary; they reflect what was tested in clinical trials. When a treatment was studied in people aged 50 to 85 with mild cognitive impairment, the drug’s approval was limited to that population.
Doctors cannot legally prescribe outside of FDA-approved indications without documented justification. This creates a catch-22 for some patients: they may have dementia that resembles the condition in the trial, but one detail—perhaps they’re slightly older, or their kidney function is slightly reduced—makes them ineligible. Insurance eligibility adds another layer. A patient might meet clinical criteria for a treatment, but their insurance company might have additional requirements: prior authorization, proof that other treatments failed first, or requirements to use specific imaging centers. Some patients delay diagnosis specifically because they fear finding out they have a condition they cannot afford to treat.
Why Biomarkers Have Become Central to Modern Eligibility
The shift toward biomarker-based eligibility represents a major change in dementia treatment. Rather than relying solely on cognitive symptoms, newer treatments increasingly require objective evidence of pathology—amyloid, tau, or neurodegeneration shown on imaging or blood tests. This is more precise scientifically, but it creates a significant limitation: access to these biomarkers is unequal. An urban academic medical center can order amyloid PET scans and blood tests for phosphorylated tau; a rural practice or community clinic often cannot. A person in a metropolitan area with specialized memory clinics might complete biomarker testing within two months of symptoms; someone in a smaller city might wait a year or more, if they can access testing at all.
During that time, they remain ineligible for treatments that could help. Some Medicare Advantage plans and commercial insurers now cover blood-based biomarker tests, making this more accessible than before, but coverage is inconsistent and varies by plan and geography. Additionally, the requirement for biomarkers can discourage testing altogether. A person worried about dementia might avoid seeking diagnosis if they know that getting tested could result in being labeled with a disease they cannot treat. This paradox—that advancing our ability to identify early disease has also made people more cautious about seeking diagnosis—is a warning sign that eligibility requirements need careful management at the community level.
The Role of Cognitive Testing in Determining Who Qualifies
Cognitive testing scores determine eligibility for many treatments and clinical trials. Mini-Cog, Montreal Cognitive Assessment, or more comprehensive neuropsychological testing provides objective data about impairment level. A person who scores in the mild cognitive impairment range on these tests may qualify for disease-modifying treatments; someone who scores in the normal range does not, even if they have subjective symptoms. Someone with moderate dementia may be ineligible for preventive treatments but eligible for symptom-management options. The challenge is that cognitive testing itself requires resources and specialist access. A general practitioner can administer a Mini-Cog in a 10-minute office visit, but more detailed testing requires a neuropsychologist and can take hours.
Insurance often requires a referral or may not cover the full cost. A person who might qualify for a treatment they need may never find out because they never completed the cognitive assessment. Real-world example: A 68-year-old woman reports increasing forgetfulness but is healthy otherwise. Her primary care doctor administers a Mini-Cog during a routine visit, and she performs in the normal range despite her concerns. Six months later, her memory problems worsen, but she doesn’t return for testing until a year after her first visit. By then, she’s declined into mild cognitive impairment range—and by this point, she may have missed the opportunity to enroll in clinical trials that required earlier stages of cognitive decline.
Insurance and Coverage Eligibility: A Separate Barrier
Clinical eligibility and insurance eligibility are often different paths, creating confusion for patients and families. A neurologist may determine that a patient meets all clinical criteria for a disease-modifying Alzheimer’s drug, but the insurance company requires prior authorization, documented cognitive decline on two visits, or failure of less expensive treatments first. Some insurers specifically exclude people over a certain age or with certain comorbidities from coverage, even when the patient meets clinical criteria. Medicare coverage for disease-modifying treatments has expanded significantly in recent years, but traditional Medicare, Medicare Advantage, Medicaid, and commercial insurance all have different coverage policies.
A 75-year-old with excellent kidney function and mild cognitive impairment might be clinically eligible for lecanemab, but if their Medicare Advantage plan excludes people over 75, or requires an amyloid PET scan from a specific imaging center, access becomes impossible. This comparison illustrates a larger issue: clinical eligibility does not equal real-world access. For uninsured or underinsured patients, eligibility becomes academic. Some manufacturers offer patient assistance programs that provide free medications to people who cannot afford them, but eligibility for these programs is separate from clinical and insurance eligibility, and awareness of these programs is often limited.
Clinical Trial Eligibility: Opportunity and Exclusion
Clinical trials are often the only way to access experimental treatments before they’re approved, but trial eligibility is notoriously restrictive. Trials typically exclude people with concurrent medical conditions, those taking certain medications, people living in care facilities, and sometimes even people with mild comorbidities like well-controlled diabetes. The reasoning is sound from a research perspective—strict inclusion and exclusion criteria make it easier to measure the drug’s effect—but the result is that trials often enroll people who are healthier and less complex than the broader dementia population. A warning here: being excluded from a clinical trial can feel like a personal rejection, but it almost never reflects how a person would actually respond to the treatment. It reflects the trial’s study design.
Someone excluded from one trial might be eligible for another, or might become eligible as more trials open and eligibility criteria become more inclusive. Research is gradually shifting toward pragmatic trials that include more real-world patients, but this shift is slow. Additionally, geography limits trial access. Most clinical trials run at academic medical centers and major hospitals in urban areas. A person in a rural area faces a choice: travel hundreds of miles for trial participation, or forgo the opportunity. Some trials now include telemedicine visits and local lab draws, but this is still evolving.
Equity, Demographics, and Eligibility Gaps
Dementia affects people across racial and ethnic groups, but clinical trials and treatments have historically enrolled predominantly white participants. This creates a concerning gap: most evidence about drug efficacy comes from studies that didn’t include diverse populations. As a result, determining whether a given person will respond to a treatment becomes less certain when that person comes from a group underrepresented in the trials that generated the evidence.
Additionally, socioeconomic factors affect eligibility in less obvious ways. Underinsured or uninsured patients are less likely to have had early cognitive testing, less likely to have access to biomarker assessment, and less likely to know about clinical trial opportunities. A person without reliable transportation or who cannot take time off work to attend frequent monitoring appointments faces practical eligibility barriers that formal criteria don’t capture. These gaps are particularly acute for Black Americans and Latinx Americans, who have higher dementia prevalence but lower access to early diagnosis and specialized care.
The Future of Treatment Eligibility: Toward More Precision and Access
Eligibility criteria are becoming more nuanced as our understanding of dementia subtypes advances. Rather than a single “Alzheimer’s disease” eligibility pathway, there are increasingly distinct criteria based on biomarker profiles, genetic factors, and pathological subtypes. This allows more targeted, precise treatment—but only if patients can access the testing and specialist care needed to determine their exact profile.
Looking forward, blood-based biomarkers will likely make eligibility assessment more accessible and less expensive than today’s imaging-heavy approach. Home-based cognitive testing and telemedicine follow-up visits may reduce geographic barriers. Broader clinical trial designs that include more diverse participants and people with multiple medical conditions could eventually shift eligibility toward real-world applicability. But these changes require investment in infrastructure, training, and equitable care delivery—not just research advances.
Conclusion
Treatment eligibility determines which patients can access which treatments, making it one of the most consequential but least understood aspects of dementia care. Eligibility is based on clinical criteria (cognitive scores, biomarkers, age, health status), insurance coverage rules, and trial-specific requirements, and all three layers must align for access to happen.
Understanding these thresholds helps patients, families, and caregivers plan realistically, seek diagnosis at the right time, and advocate for access when barriers arise. The path forward requires expanding equitable access to biomarker testing and cognitive assessment, streamlining insurance authorization for eligible patients, and designing trials that reflect the real diversity of the dementia population. If you’re navigating treatment options for yourself or a loved one with dementia, ask your healthcare provider explicitly: What treatments are you eligible for right now? What criteria would make you eligible for others? What barriers—clinical, financial, or practical—stand between eligibility and actual access? These conversations can clarify what’s truly available and what next steps make sense.
Frequently Asked Questions
Can a doctor prescribe a dementia treatment to someone who doesn’t meet the official eligibility criteria?
In some cases, yes—this is called off-label use. Doctors can prescribe medications outside their FDA-approved indication if they believe it’s appropriate for a patient. However, insurance companies may refuse to cover off-label treatment, and doctors are cautious about liability. Any off-label use should be a detailed conversation between the patient and their physician about the evidence and risks.
What should I do if I’m clinically eligible for a treatment but my insurance denies coverage?
Request a peer-to-peer review, where your doctor speaks directly with the insurance company’s medical team. Ask whether prior authorization requirements or appeals processes could change the decision. If you continue to be denied, patient assistance programs from drug manufacturers sometimes provide medications free of charge. Your neurologist’s office staff often have experience navigating these denials and can help advocate.
How do I know if I’m eligible for a clinical trial?
Clinical trial eligibility is trial-specific, but you can search ClinicalTrials.gov to find trials in your area. Review the eligibility criteria, and contact the trial directly with questions. Trials sometimes have flexibility with borderline criteria, though they cannot enroll people who don’t meet the core requirements.
Does having only mild cognitive impairment mean I can access more treatments?
Potentially, yes. Many disease-modifying treatments target earlier stages of cognitive decline, making mild cognitive impairment a key window for access. However, you need documented cognitive impairment to be eligible—subjective symptoms alone are not sufficient. This is why early cognitive testing matters.
If a new dementia drug is approved, will I automatically become eligible for it?
Not necessarily. Approval establishes what the FDA considers safe and effective, but your personal eligibility depends on the drug’s specific indications (approved uses), your cognitive status, biomarker profile, age, health, insurance coverage, and access to any required testing. You would need to discuss with your neurologist whether you meet that particular drug’s criteria.
Are clinical trial eligibility criteria the same as real-world treatment eligibility?
No. Clinical trials use narrow criteria to generate clear evidence, while real-world prescribing can sometimes be more flexible. However, real-world treatment still requires meeting the FDA’s approved indications and insurance coverage rules, so trial-tight criteria don’t always become looser once a treatment is approved.
